LpMab-23-recognizing cancer-type podoplanin is a novel predictor for a poor prognosis of early stage tongue cancer

PURPOSE: We report that the reactivity of a novel monoclonal antibody LpMab-23 for human cancer-type podoplanin (PDPN) is a predictor for a poor prognosis of tongue cancer. PATIENTS AND METHODS: The association between LpMab-23-recognizing cancer-type PDPN expression and clinical/pathological featur...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Miyazaki, Akihiro, Nakai, Hiromi, Sonoda, Tomoko, Hirohashi, Yoshihiko, Kaneko, Mika K., Kato, Yukinari, Sawa, Yoshihiko, Hiratsuka, Hiroyoshi
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2018
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5940393/
https://ncbi.nlm.nih.gov/pubmed/29765527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24986
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg